Mauro Delorenzi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mauro Delorenzi has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Sabine Tejpar
UZ Leuven
4 shared publications - Fred T. Bosman
University Medical Center Lausanne
3 shared publications - Nouria Hernandez
Center for Integrative Genomics, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
3 shared publications - Pratyaksha Wirapati
Swiss Institute of Bioinformatics, Lausanne, Switzerland
3 shared publications - Vlad Popovici
Masarykova Univerzita, RECETOX Brno Czech Republic
3 shared publications Arnaud D. Roth
Oncology, Hôpitaux Universitaires de Genève, Genève, Switzerland
2 shared publications
Latest Publications
- Open Access
- 30 November 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (12) , 3185
Targeting of the NOX1/ADAM17 Enzymatic Complex Regulates Soluble MCAM-Dependent Pro-Tumorigenic Activity in Colorectal Cancer
The melanoma cell adhesion molecule, shed from endothelial and cancer cells, is a soluble growth factor that induces tumor angiogenesis and growth. However, the molecular mechanism accounting for its generation in a tumor context is still unclear. To investigate this mechanism, we performed in vitro experiments with endothelial/cancer cells, gene expression analyses on datasets from human colorectal tumor samples, and applied pharmacological methods in vitro/in vivo with mouse and human colorectal cancer cells. We found that soluble MCAM generation is governed by ADAM17 proteolytic activity and NOX1-regulating ADAM17 expression. The treatment of colorectal tumor-bearing mice with pharmacologic NOX1 inhibitors or tumor growth in NOX1-deficient mice reduced the blood concentration of soluble MCAM and abrogated the anti-tumor effects of anti-soluble MCAM antibodies while ADAM17 pharmacologic inhibitors reduced tumor growth and angiogenesis in vivo. Especially, the expression of MCAM, NOX1, and ADAM17 was more prominent in the angiogenic, colorectal cancer-consensus molecular subtype 4 where high MCAM expression correlated with angiogenic and lymphangiogenic markers. Finally, we demonstrated that soluble MCAM also acts as a lymphangiogenic factor in vitro. These results identify a role for NOX1/ADAM17 in soluble MCAM generation, with potential clinical therapeutic relevance to the aggressive, angiogenic CMS4 colorectal cancer subtype.
- 30 November 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (12) , 3185
Open AccessTargeting of the NOX1/ADAM17 Enzymatic Complex Regulates Soluble MCAM-Dependent Pro-Tumorigenic Activity in Colorectal Cancer
The melanoma cell adhesion molecule, shed from endothelial and cancer cells, is a soluble growth factor that induces tumor angiogenesis and growth. However, the molecular mechanism accounting for its generation in a tumor context is still unclear. To investigate this mechanism, we performed in vitro experiments with endothelial/cancer cells, gene expression analyses on datasets from human colorectal tumor samples, and applied pharmacological methods in vitro/in vivo with mouse and human colorectal cancer cells. We found that soluble MCAM generation is governed by ADAM17 proteolytic activity and NOX1-regulating ADAM17 expression. The treatment of colorectal tumor-bearing mice with pharmacologic NOX1 inhibitors or tumor growth in NOX1-deficient mice reduced the blood concentration of soluble MCAM and abrogated the anti-tumor effects of anti-soluble MCAM antibodies while ADAM17 pharmacologic inhibitors reduced tumor growth and angiogenesis in vivo. Especially, the expression of MCAM, NOX1, and ADAM17 was more prominent in the angiogenic, colorectal cancer-consensus molecular subtype 4 where high MCAM expression correlated with angiogenic and lymphangiogenic markers. Finally, we demonstrated that soluble MCAM also acts as a lymphangiogenic factor in vitro. These results identify a role for NOX1/ADAM17 in soluble MCAM generation, with potential clinical therapeutic relevance to the aggressive, angiogenic CMS4 colorectal cancer subtype.
- Open Access
Targeting OLFML3 in Colorectal Cancer Suppresses Tumor Growth and Angiogenesis, and Increases the Efficacy of Anti-PD1 Based Immunotherapy
The role of the proangiogenic factor olfactomedin-like 3 (OLFML3) in cancer is unclear. To characterize OLFML3 expression in human cancer and its role during tumor development, we undertook tissue expression studies, gene expression analyses of patient tumor samples, in vivo studies in mouse cancer models, and in vitro coculture experiments. OLFML3 was expressed at high levels, mainly in blood vessels, in multiple human cancers. We focused on colorectal cancer (CRC), as elevated expression of OLFML3 mRNA correlated with shorter relapse-free survival, higher tumor grade, and angiogenic microsatellite stable consensus molecular subtype 4 (CMS4). Treatment of multiple in vivo tumor models with OLFML3-blocking antibodies and deletion of the Olfml3 gene from mice decreased lymphangiogenesis, pericyte coverage, and tumor growth. Antibody-mediated blockade of OLFML3 and deletion of host Olfml3 decreased the recruitment of tumor-promoting tumor-associated macrophages and increased infiltration of the tumor microenvironment by NKT cells. Importantly, targeting OLFML3 increased the antitumor efficacy of anti-PD-1 checkpoint inhibitor therapy. Taken together, the results demonstrate that OLFML3 is a promising candidate therapeutic target for CRC.
Open AccessTargeting OLFML3 in Colorectal Cancer Suppresses Tumor Growth and Angiogenesis, and Increases the Efficacy of Anti-PD1 Based Immunotherapy
The role of the proangiogenic factor olfactomedin-like 3 (OLFML3) in cancer is unclear. To characterize OLFML3 expression in human cancer and its role during tumor development, we undertook tissue expression studies, gene expression analyses of patient tumor samples, in vivo studies in mouse cancer models, and in vitro coculture experiments. OLFML3 was expressed at high levels, mainly in blood vessels, in multiple human cancers. We focused on colorectal cancer (CRC), as elevated expression of OLFML3 mRNA correlated with shorter relapse-free survival, higher tumor grade, and angiogenic microsatellite stable consensus molecular subtype 4 (CMS4). Treatment of multiple in vivo tumor models with OLFML3-blocking antibodies and deletion of the Olfml3 gene from mice decreased lymphangiogenesis, pericyte coverage, and tumor growth. Antibody-mediated blockade of OLFML3 and deletion of host Olfml3 decreased the recruitment of tumor-promoting tumor-associated macrophages and increased infiltration of the tumor microenvironment by NKT cells. Importantly, targeting OLFML3 increased the antitumor efficacy of anti-PD-1 checkpoint inhibitor therapy. Taken together, the results demonstrate that OLFML3 is a promising candidate therapeutic target for CRC.
- Open Access
- 1 January 2017
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (1) , 104-115
BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Purpose: Mutation of BRAF at the valine 600 residue occurs in approximately 10% of colorectal cancers, a group with particularly poor prognosis. The response of BRAF mutant colorectal cancer to recent targeted strategies such as anti-BRAF or combinations with MEK and EGFR inhibitors remains limited and highly heterogeneous within BRAF V600E cohorts. There is clearly an unmet need in understanding the biology of BRAF V600E colorectal cancers and potential subgroups within this population. Experimental Design: In the biggest yet reported cohort of 218 BRAF V600E with gene expression data, we performed unsupervised clustering using non-negative matrix factorization to identify gene expression–based subgroups and characterized pathway activation. Results: We found strong support for a split into two distinct groups, called BM1 and BM2. These subtypes are independent of MSI status, PI3K mutation, gender, and sidedness. Pathway analyses revealed that BM1 is characterized by KRAS/AKT pathway activation, mTOR/4EBP deregulation, and EMT whereas BM2 displays important deregulation of the cell cycle. Proteomics data validated these observations as BM1 is characterized by high phosphorylation levels of AKT and 4EBP1, and BM2 patients display high CDK1 and low cyclin D1 levels. We provide a global assessment of gene expression motifs that differentiate BRAF V600E subtypes from other colorectal cancers. Conclusions: We suggest that BRAF mutant patients should not be considered as having a unique biology and provide an in depth characterization of heterogeneous motifs that may be exploited for drug targeting. Clin Cancer Res; 23(1); 104–15. ©2016 AACR.
- 1 January 2017
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 23 (1) , 104-115
Open AccessBRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression
Purpose: Mutation of BRAF at the valine 600 residue occurs in approximately 10% of colorectal cancers, a group with particularly poor prognosis. The response of BRAF mutant colorectal cancer to recent targeted strategies such as anti-BRAF or combinations with MEK and EGFR inhibitors remains limited and highly heterogeneous within BRAF V600E cohorts. There is clearly an unmet need in understanding the biology of BRAF V600E colorectal cancers and potential subgroups within this population. Experimental Design: In the biggest yet reported cohort of 218 BRAF V600E with gene expression data, we performed unsupervised clustering using non-negative matrix factorization to identify gene expression–based subgroups and characterized pathway activation. Results: We found strong support for a split into two distinct groups, called BM1 and BM2. These subtypes are independent of MSI status, PI3K mutation, gender, and sidedness. Pathway analyses revealed that BM1 is characterized by KRAS/AKT pathway activation, mTOR/4EBP deregulation, and EMT whereas BM2 displays important deregulation of the cell cycle. Proteomics data validated these observations as BM1 is characterized by high phosphorylation levels of AKT and 4EBP1, and BM2 patients display high CDK1 and low cyclin D1 levels. We provide a global assessment of gene expression motifs that differentiate BRAF V600E subtypes from other colorectal cancers. Conclusions: We suggest that BRAF mutant patients should not be considered as having a unique biology and provide an in depth characterization of heterogeneous motifs that may be exploited for drug targeting. Clin Cancer Res; 23(1); 104–15. ©2016 AACR.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11525
Comparison of predictors of metastatic liver tropism between tumors of epithelial and non-epithelial origin.
11525 Background: Uveal melanoma has a striking propensity for liver metastasis that is not explained by anatomical factors. The biological features that confer this behavior could be a useful predictor of liver metastasis when applied in other tumor types, especially colorectal cancer, where the treatment of liver lesions with curative intent can be considered. Methods: We used our previously published dataset of microarray gene expression data from 76 uveal melanoma patients, a newer cohort of 80 patients that we studied with RNAseq and a publicly available microarray study of uveal melanoma with 57 patients to compile a meta-analysis. Metastasis-free survival models were fit independently for all genes, after adjustment for the status of chromosome 3. The hazard coefficients from each dataset were then combined in a mixed effects model. The top statistically significant genes were used to build a predictive model with the GLMnet algorithm, which performs optimized feature selection and cross-validation performance estimation. Results: After removal of patients and genes with incomplete information we obtained a database of 196 uveal melanoma patients and 13392 genes. The concordance of significant genes between datasets was excellent. The most predictive model for liver metastasis combined two genes: PTP4A3 and JPH1. We validated this model for the prediction of liver metastasis in data from the PETACC-3 study of adjuvant chemotherapy in colorectal cancer. Indeed, the model was predictive of liver metastasis in colorectal cancer patients (n = 446, p= 0.001, HR = 2.27), even after multivariate adjustment for stage, MSI status and treatment group. Based on public data from The Cancer Genome Atlas, the model was also predictive of liver metastasis in gastric cancer patients (n = 217, p= 0.027, HR 4.02), after adjustment for stage. Conclusions: The genes driving liver metastasis of uveal melanoma also participate in the hepatic spread of digestive tumors. Our work provides a unifying view of the biology underlying this metastatic process and will be validated prospectively in other tumor types. Defining the contribution of JPH1 is an opportunity for further biological studies.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 11525
Comparison of predictors of metastatic liver tropism between tumors of epithelial and non-epithelial origin.
11525 Background: Uveal melanoma has a striking propensity for liver metastasis that is not explained by anatomical factors. The biological features that confer this behavior could be a useful predictor of liver metastasis when applied in other tumor types, especially colorectal cancer, where the treatment of liver lesions with curative intent can be considered. Methods: We used our previously published dataset of microarray gene expression data from 76 uveal melanoma patients, a newer cohort of 80 patients that we studied with RNAseq and a publicly available microarray study of uveal melanoma with 57 patients to compile a meta-analysis. Metastasis-free survival models were fit independently for all genes, after adjustment for the status of chromosome 3. The hazard coefficients from each dataset were then combined in a mixed effects model. The top statistically significant genes were used to build a predictive model with the GLMnet algorithm, which performs optimized feature selection and cross-validation performance estimation. Results: After removal of patients and genes with incomplete information we obtained a database of 196 uveal melanoma patients and 13392 genes. The concordance of significant genes between datasets was excellent. The most predictive model for liver metastasis combined two genes: PTP4A3 and JPH1. We validated this model for the prediction of liver metastasis in data from the PETACC-3 study of adjuvant chemotherapy in colorectal cancer. Indeed, the model was predictive of liver metastasis in colorectal cancer patients (n = 446, p= 0.001, HR = 2.27), even after multivariate adjustment for stage, MSI status and treatment group. Based on public data from The Cancer Genome Atlas, the model was also predictive of liver metastasis in gastric cancer patients (n = 217, p= 0.027, HR 4.02), after adjustment for stage. Conclusions: The genes driving liver metastasis of uveal melanoma also participate in the hepatic spread of digestive tumors. Our work provides a unifying view of the biology underlying this metastatic process and will be validated prospectively in other tumor types. Defining the contribution of JPH1 is an opportunity for further biological studies.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3519
Prognostication using molecular (mol) markers and clinicopathological (clpath) features in high-risk stage II/III colon cancer (CC).
3519 Background: AJCC v.7 staging and clpath covariates do not accurately predict outcome of CC patients (pts) eligible for adjuvant chemotherapy (adjCh). Mol markers, microsatellite instability (MSI) and mutations (mut) in BRAF and KRAS, may further improve prognostication in high-risk CC. Methods: Data from 4,796 stage II/III pts accrued to phase 3 trials PETACC3 and N0147 (train set) were used to construct Cox models for overall survival (OS). Variables included stage (pT, pN); clpath (# lymph nodes [LNs] positive, # LNs assessed, tumor grade, primary site, age, gender, adjCh); and mol (MSI, BRAF and KRAS mut). Final models (1. TNM; 2. TNM + mol; 3. TNM + clpath; 4. TNM + clpath + mol) were internally (train set) and externally (test set) validated on 597 stage II/III treated pts from non-clinical trial cohorts. Results: All examined traits were statistically significant for OS prediction (Table 1). We found significant interaction between site and MSI (p=.03) in multivariate models, with worse OS for MSI vs MSS left CC (HR 1.22) and better OS for right CC (HR 0.70). Models 1 to 4 associated with C-indices of 0.65, 0.68, 0.70, 0.72, respectively, in train set; and 0.68, 0.71, 0.73, 0.74 in test set. Corresponding time-dependent AUCs (5 years summary) were 0.54, 0.66, 0.73, 0.74 in train set; and 0.55, 0.68, 0.72, 0.73 in test set. Conclusions: Incorporation of mol markers (MSI, BRAF and KRAS mut) improves prognostic estimation in stage II/III CC pts treated with adjCh. We propose their prospective assessment in larger clinical cohorts, including untreated pts, and development of online calculators that could aid in prognostication (model-based staging) and patient/physician communication.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 3519
Prognostication using molecular (mol) markers and clinicopathological (clpath) features in high-risk stage II/III colon cancer (CC).
3519 Background: AJCC v.7 staging and clpath covariates do not accurately predict outcome of CC patients (pts) eligible for adjuvant chemotherapy (adjCh). Mol markers, microsatellite instability (MSI) and mutations (mut) in BRAF and KRAS, may further improve prognostication in high-risk CC. Methods: Data from 4,796 stage II/III pts accrued to phase 3 trials PETACC3 and N0147 (train set) were used to construct Cox models for overall survival (OS). Variables included stage (pT, pN); clpath (# lymph nodes [LNs] positive, # LNs assessed, tumor grade, primary site, age, gender, adjCh); and mol (MSI, BRAF and KRAS mut). Final models (1. TNM; 2. TNM + mol; 3. TNM + clpath; 4. TNM + clpath + mol) were internally (train set) and externally (test set) validated on 597 stage II/III treated pts from non-clinical trial cohorts. Results: All examined traits were statistically significant for OS prediction (Table 1). We found significant interaction between site and MSI (p=.03) in multivariate models, with worse OS for MSI vs MSS left CC (HR 1.22) and better OS for right CC (HR 0.70). Models 1 to 4 associated with C-indices of 0.65, 0.68, 0.70, 0.72, respectively, in train set; and 0.68, 0.71, 0.73, 0.74 in test set. Corresponding time-dependent AUCs (5 years summary) were 0.54, 0.66, 0.73, 0.74 in train set; and 0.55, 0.68, 0.72, 0.73 in test set. Conclusions: Incorporation of mol markers (MSI, BRAF and KRAS mut) improves prognostic estimation in stage II/III CC pts treated with adjCh. We propose their prospective assessment in larger clinical cohorts, including untreated pts, and development of online calculators that could aid in prognostication (model-based staging) and patient/physician communication.
- Open Access
- 23 February 2015
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 107 (5) , djv056
Response
We appreciate the comments of Donna Graham et al. on our recent article ( 1 ). The first issue they raise concerns the use of an adjuvant treated patient cohort for risk scores intended to assist in decisions regarding whether or not such treatment should be administered at all. While we agree with this perception, we also contend that prognostic signatures so far have failed to provide information on likelihood of response to drugs in the adjuvant setting, which implies that they represent inherent prognostic groups, the outcome of which is not improved by therapy. This is an issue in itself, but beyond the scope of our paper. In absence of such evidence, a treated patient cohort is potentially as informative on the prognostic groups.
- 23 February 2015
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 107 (5) , djv056
Open AccessResponse
We appreciate the comments of Donna Graham et al. on our recent article ( 1 ). The first issue they raise concerns the use of an adjuvant treated patient cohort for risk scores intended to assist in decisions regarding whether or not such treatment should be administered at all. While we agree with this perception, we also contend that prognostic signatures so far have failed to provide information on likelihood of response to drugs in the adjuvant setting, which implies that they represent inherent prognostic groups, the outcome of which is not improved by therapy. This is an issue in itself, but beyond the scope of our paper. In absence of such evidence, a treated patient cohort is potentially as informative on the prognostic groups.
- Open Access
- 27 January 2015
- Published by Springer Nature in Genome Biology
- Vol. 16 (1) , 16
Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma
Background: HOX genes are a family of developmental genes that are expressed neither in the developing forebrain nor in the normal brain. Aberrant expression of a HOX-gene dominated stem-cell signature in glioblastoma has been linked with increased resistance to chemo-radiotherapy and sustained proliferation of glioma initiating cells. Here we describe the epigenetic and genetic alterations and their interactions associated with the expression of this signature in glioblastoma. Results: We observe prominent hypermethylation of the HOXA locus 7p15.2 in glioblastoma in contrast to non-tumoral brain. Hypermethylation is associated with a gain of chromosome 7, a hallmark of glioblastoma, and may compensate for tumor-driven enhanced gene dosage as a rescue mechanism by preventing undue gene expression. We identify the CpG island of the HOXA10 alternative promoter that appears to escape hypermethylation in the HOX-high glioblastoma. An additive effect of gene copy gain at 7p15.2 and DNA methylation at key regulatory CpGs in HOXA10 is significantly associated with HOX-signature expression. Additionally, we show concordance between methylation status and presence of active or inactive chromatin marks in glioblastoma-derived spheres that are HOX-high or HOX-low, respectively. Conclusions: Based on these findings, we propose co-evolution and interaction between gene copy gain, associated with a gain of chromosome 7, and additional epigenetic alterations as key mechanisms triggering a coordinated, but inappropriate, HOX transcriptional program in glioblastoma.
- 27 January 2015
- Published by Springer Nature in Genome Biology
- Vol. 16 (1) , 16
Open AccessChromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma
Background: HOX genes are a family of developmental genes that are expressed neither in the developing forebrain nor in the normal brain. Aberrant expression of a HOX-gene dominated stem-cell signature in glioblastoma has been linked with increased resistance to chemo-radiotherapy and sustained proliferation of glioma initiating cells. Here we describe the epigenetic and genetic alterations and their interactions associated with the expression of this signature in glioblastoma. Results: We observe prominent hypermethylation of the HOXA locus 7p15.2 in glioblastoma in contrast to non-tumoral brain. Hypermethylation is associated with a gain of chromosome 7, a hallmark of glioblastoma, and may compensate for tumor-driven enhanced gene dosage as a rescue mechanism by preventing undue gene expression. We identify the CpG island of the HOXA10 alternative promoter that appears to escape hypermethylation in the HOX-high glioblastoma. An additive effect of gene copy gain at 7p15.2 and DNA methylation at key regulatory CpGs in HOXA10 is significantly associated with HOX-signature expression. Additionally, we show concordance between methylation status and presence of active or inactive chromatin marks in glioblastoma-derived spheres that are HOX-high or HOX-low, respectively. Conclusions: Based on these findings, we propose co-evolution and interaction between gene copy gain, associated with a gain of chromosome 7, and additional epigenetic alterations as key mechanisms triggering a coordinated, but inappropriate, HOX transcriptional program in glioblastoma.
- Open Access
- 3 December 2014
- Published by Springer Nature in BMC Plant Biology
- Vol. 14 (1) , 333
A novel bioinformatics pipeline to discover genes related to arbuscular mycorrhizal symbiosis based on their evolutionary conservation pattern among higher plants
Genes involved in arbuscular mycorrhizal (AM) symbiosis have been identified primarily by mutant screens, followed by identification of the mutated genes (forward genetics). In addition, a number of AM-related genes has been identified by their AM-related expression patterns, and their function has subsequently been elucidated by knock-down or knock-out approaches (reverse genetics). However, genes that are members of functionally redundant gene families, or genes that have a vital function and therefore result in lethal mutant phenotypes, are difficult to identify. If such genes are constitutively expressed and therefore escape differential expression analyses, they remain elusive. The goal of this study was to systematically search for AM-related genes with a bioinformatics strategy that is insensitive to these problems. The central element of our approach is based on the fact that many AM-related genes are conserved only among AM-competent species. Our approach involves genome-wide comparisons at the proteome level of AM-competent host species with non-mycorrhizal species. Using a clustering method we first established orthologous/paralogous relationships and subsequently identified protein clusters that contain members only of the AM-competent species. Proteins of these clusters were then analyzed in an extended set of 16 plant species and ranked based on their relatedness among AM-competent monocot and dicot species, relative to non-mycorrhizal species. In addition, we combined the information on the protein-coding sequence with gene expression data and with promoter analysis. As a result we present a list of yet uncharacterized proteins that show a strongly AM-related pattern of sequence conservation, indicating that the respective genes may have been under selection for a function in AM. Among the top candidates are three genes that encode a small family of similar receptor-like kinases that are related to the S-locus receptor kinases involved in sporophytic self-incompatibility. We present a new systematic strategy of gene discovery based on conservation of the protein-coding sequence that complements classical forward and reverse genetics. This strategy can be applied to diverse other biological phenomena if species with established genome sequences fall into distinguished groups that differ in a defined functional trait of interest.
- 3 December 2014
- Published by Springer Nature in BMC Plant Biology
- Vol. 14 (1) , 333
Open AccessA novel bioinformatics pipeline to discover genes related to arbuscular mycorrhizal symbiosis based on their evolutionary conservation pattern among higher plants
Genes involved in arbuscular mycorrhizal (AM) symbiosis have been identified primarily by mutant screens, followed by identification of the mutated genes (forward genetics). In addition, a number of AM-related genes has been identified by their AM-related expression patterns, and their function has subsequently been elucidated by knock-down or knock-out approaches (reverse genetics). However, genes that are members of functionally redundant gene families, or genes that have a vital function and therefore result in lethal mutant phenotypes, are difficult to identify. If such genes are constitutively expressed and therefore escape differential expression analyses, they remain elusive. The goal of this study was to systematically search for AM-related genes with a bioinformatics strategy that is insensitive to these problems. The central element of our approach is based on the fact that many AM-related genes are conserved only among AM-competent species. Our approach involves genome-wide comparisons at the proteome level of AM-competent host species with non-mycorrhizal species. Using a clustering method we first established orthologous/paralogous relationships and subsequently identified protein clusters that contain members only of the AM-competent species. Proteins of these clusters were then analyzed in an extended set of 16 plant species and ranked based on their relatedness among AM-competent monocot and dicot species, relative to non-mycorrhizal species. In addition, we combined the information on the protein-coding sequence with gene expression data and with promoter analysis. As a result we present a list of yet uncharacterized proteins that show a strongly AM-related pattern of sequence conservation, indicating that the respective genes may have been under selection for a function in AM. Among the top candidates are three genes that encode a small family of similar receptor-like kinases that are related to the S-locus receptor kinases involved in sporophytic self-incompatibility. We present a new systematic strategy of gene discovery based on conservation of the protein-coding sequence that complements classical forward and reverse genetics. This strategy can be applied to diverse other biological phenomena if species with established genome sequences fall into distinguished groups that differ in a defined functional trait of interest.
- Open Access
- 22 September 2014
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 106 (10)
Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data
Prognosis prediction for resected primary colon cancer is based on the T-stage Node Metastasis (TNM) staging system. We investigated if four well-documented gene expression risk scores can improve patient stratification. Microarray-based versions of risk-scores were applied to a large independent cohort of 688 stage II/III tumors from the PETACC-3 trial. Prognostic value for relapse-free survival (RFS), survival after relapse (SAR), and overall survival (OS) was assessed by regression analysis. To assess improvement over a reference, prognostic model was assessed with the area under curve (AUC) of receiver operating characteristic (ROC) curves. All statistical tests were two-sided, except the AUC increase. All four risk scores (RSs) showed a statistically significant association (single-test, P < .0167) with OS or RFS in univariate models, but with HRs below 1.38 per interquartile range. Three scores were predictors of shorter RFS, one of shorter SAR. Each RS could only marginally improve an RFS or OS model with the known factors T-stage, N-stage, and microsatellite instability (MSI) status (AUC gains < 0.025 units). The pairwise interscore discordance was never high (maximal Spearman correlation = 0.563) A combined score showed a trend to higher prognostic value and higher AUC increase for OS (HR = 1.74, 95% confidence interval [CI] = 1.44 to 2.10, P < .001, AUC from 0.6918 to 0.7321) and RFS (HR = 1.56, 95% CI = 1.33 to 1.84, P < .001, AUC from 0.6723 to 0.6945) than any single score. The four tested gene expression–based risk scores provide prognostic information but contribute only marginally to improving models based on established risk factors. A combination of the risk scores might provide more robust information. Predictors of RFS and SAR might need to be different.
- 22 September 2014
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 106 (10)
Open AccessTest of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data
Prognosis prediction for resected primary colon cancer is based on the T-stage Node Metastasis (TNM) staging system. We investigated if four well-documented gene expression risk scores can improve patient stratification. Microarray-based versions of risk-scores were applied to a large independent cohort of 688 stage II/III tumors from the PETACC-3 trial. Prognostic value for relapse-free survival (RFS), survival after relapse (SAR), and overall survival (OS) was assessed by regression analysis. To assess improvement over a reference, prognostic model was assessed with the area under curve (AUC) of receiver operating characteristic (ROC) curves. All statistical tests were two-sided, except the AUC increase. All four risk scores (RSs) showed a statistically significant association (single-test, P < .0167) with OS or RFS in univariate models, but with HRs below 1.38 per interquartile range. Three scores were predictors of shorter RFS, one of shorter SAR. Each RS could only marginally improve an RFS or OS model with the known factors T-stage, N-stage, and microsatellite instability (MSI) status (AUC gains < 0.025 units). The pairwise interscore discordance was never high (maximal Spearman correlation = 0.563) A combined score showed a trend to higher prognostic value and higher AUC increase for OS (HR = 1.74, 95% confidence interval [CI] = 1.44 to 2.10, P < .001, AUC from 0.6918 to 0.7321) and RFS (HR = 1.56, 95% CI = 1.33 to 1.84, P < .001, AUC from 0.6723 to 0.6945) than any single score. The four tested gene expression–based risk scores provide prognostic information but contribute only marginally to improving models based on established risk factors. A combination of the risk scores might provide more robust information. Predictors of RFS and SAR might need to be different.
- Open Access
- 7 April 2014
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 24 (7) , 1157-1168
Quantifying ChIP-seq data: a spiking method providing an internal reference for sample-to-sample normalization
Chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) experiments are widely used to determine, within entire genomes, the occupancy sites of any protein of interest, including, for example, transcription factors, RNA polymerases, or histones with or without various modifications. In addition to allowing the determination of occupancy sites within one cell type and under one condition, this method allows, in principle, the establishment and comparison of occupancy maps in various cell types, tissues, and conditions. Such comparisons require, however, that samples be normalized. Widely used normalization methods that include a quantile normalization step perform well when factor occupancy varies at a subset of sites, but may miss uniform genome-wide increases or decreases in site occupancy. We describe a spike adjustment procedure (SAP) that, unlike commonly used normalization methods intervening at the analysis stage, entails an experimental step prior to immunoprecipitation. A constant, low amount from a single batch of chromatin of a foreign genome is added to the experimental chromatin. This “spike” chromatin then serves as an internal control to which the experimental signals can be adjusted. We show that the method improves similarity between replicates and reveals biological differences including global and largely uniform changes.
- 7 April 2014
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 24 (7) , 1157-1168
Open AccessQuantifying ChIP-seq data: a spiking method providing an internal reference for sample-to-sample normalization
Chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) experiments are widely used to determine, within entire genomes, the occupancy sites of any protein of interest, including, for example, transcription factors, RNA polymerases, or histones with or without various modifications. In addition to allowing the determination of occupancy sites within one cell type and under one condition, this method allows, in principle, the establishment and comparison of occupancy maps in various cell types, tissues, and conditions. Such comparisons require, however, that samples be normalized. Widely used normalization methods that include a quantile normalization step perform well when factor occupancy varies at a subset of sites, but may miss uniform genome-wide increases or decreases in site occupancy. We describe a spike adjustment procedure (SAP) that, unlike commonly used normalization methods intervening at the analysis stage, entails an experimental step prior to immunoprecipitation. A constant, low amount from a single batch of chromatin of a foreign genome is added to the experimental chromatin. This “spike” chromatin then serves as an internal control to which the experimental signals can be adjusted. We show that the method improves similarity between replicates and reveals biological differences including global and largely uniform changes.